drugset / Trial / NCT07846696
An Open Label Individual Patient (OLIP)-02 Study of Nusinersen (BIIB058)
Phase 3
Not yet recruiting
1 enrolled
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NaSingle-groupOpen-labelTreatment
Summary
An Open Label Individual Patient (OLIP) Study of Nusinersen (BIIB058) in a Participant with Spinal Muscular Atrophy Who Previously Participated in an Investigational Study with Nusinersen
Timeline
- Start
- 2026-09-17
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nusinersen | Antisense oligonucleotide | 28 mg | Intrathecal |